

Supporting information:

An all-in-one nanoparticle (AION) contrast agent for breast cancer screening with DEM-CT-MRI-NIRF imaging

Jessica C. Hsu,^{1,2} Pratap C. Naha,¹ Kristen C. Lau,^{1,2} Peter Chhour,^{1,2} Renee Hastings,¹ [Brianna F. Moon](#),^{1,2} Joel M. Stein,¹ Walter R. Witschey,¹ Elizabeth S. McDonald,¹ Andrew D. A. Maidment,¹ and David P. Cormode^{1,2,3*}

¹Department of Radiology, University of Pennsylvania 3400 Spruce St, 1 Silverstein, Philadelphia, PA 19104, USA.

²Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.

³Department of Cardiology, University of Pennsylvania, Philadelphia, PA, USA.

*Corresponding author

E-mail: david.cormode@uphs.upenn.edu; Tel: 215-615-4656; Fax: 215-662-7868




Figure S1. SEM image of AION showing the morphology of the particles (scale bar = 100 nm).




Figure S2. EDX spectrum of AION.




Figure S3. A representative EDX line scan across a single AION particle.




Figure S4. Absorption and fluorescence emission spectra of AION.




Figure S5. TEM image of AgNP with the inset showing a TEM image of as-prepared 5 nm pure silver nanoparticles (same scale bar).




Figure S6. CT attenuation (HU) vs. concentration (mg/ml) for (A) AION, (B) AgNO₃ and (C) Iopamidol at tube voltages of 80, 100, 120 and 140 kV.




Figure S7. CT attenuation rates of different agents given in unit of HU mM⁻¹ for each tube voltage. Error bars are one standard deviation.




Figure S8. Representative H&E stained micrographs of major organs including liver and spleen collected from control mice and AION treated mice at 24 hours after injection. The dose of AION was 250 mg Ag/kg. No apparent organ damage or lesion was observed from the treated mice in comparison with the control. AION in these organs are indicated by black circles. Scale bar = 100 μm .